Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | TLR2 | O60603 | 4/20 | 0.46 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.44 |
| ▸ | FABP7 | O15540 | 2/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | MDM4 | O15151 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | CASP3 | P42574 | 2/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28036073 | 1.00 | KMT2A (0.48) | KMT2ATLR2FABP5FABP7HDAC1 | |
| SCHEMBL524545 | 1.00 | KMT2A (0.48) | KMT2ATLR2FABP5FABP7HDAC1 | |
| SCHEMBL3426738 | 1.00 | KMT2A (0.48) | KMT2ATLR2FABP5FABP7HDAC1 | |
| SCHEMBL3976225 | 1.00 | KMT2A (0.48) | KMT2ATLR2FABP5FABP7HDAC1 | |
| SCHEMBL525558 | 1.00 | KMT2A (0.48) | KMT2ATLR2FABP5FABP7HDAC1 | |
| SCHEMBL25144 | 0.99 | KMT2A (0.49) | KMT2ATLR2FABP5FABP7HDAC1 | |
| SCHEMBL97613 | 0.95 | KMT2A (0.50) | KMT2ATLR2FABP5FABP7CA1 | |
| Succinic Acid SCHEMBL28760118 | 0.94 | KMT2A (0.50) | KMT2ATLR2FABP5FABP7HDAC1 | |
| Tetrahydrofuran SCHEMBL28301142 | 0.91 | KMT2A (0.43) | KMT2ATLR2FABP5FABP7HDAC1 | |
| SCHEMBL31658990 | 0.90 | KMT2A (0.44) | KMT2ATLR2FABP5FABP7HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250129125-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2025-04-24 | — | — | US | disclosed |
| US-12187816-B2 | Macrocyclic compounds and methods of use thereof | GENENTECH, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| CN-118027136-A | Paper-assisted polypeptide integrated green synthesis method | 北京中医药大学 | 2024-05-14 | — | — | CN | disclosed |
| EP-4168121-A2 | MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | Genentech, Inc. (US) | 2023-04-26 | — | — | EP | disclosed |
| CN-115702026-A | Macrocyclic compounds and methods of use thereof | 基因泰克公司 | 2023-02-14 | — | — | CN | disclosed |
| EP-4100042-A1 | REVERSE AMIDE-LINKED MELANOCORTIN RECEPTOR-SPECIFIC CYCLIC PEPTIDES | Palatin Technologies, Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| US-20220363719-A1 | Reverse Amide-Linked Melanocortin Receptor-Specific Cyclic Peptides | PALATIN TECHNOLOGIES, INC. (US) | 2022-11-17 | — | — | US | disclosed |
| CN-115279390-A | Reverse amide linked melanotropin receptor specific cyclic peptides | 帕拉丁科技公司 | 2022-11-01 | — | — | CN | disclosed |
| US-20220106361-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2022-04-07 | — | — | US | disclosed |
| WO-2021262731-A2 | MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2021-12-30 | — | — | WO | disclosed |
| US-8796202-B2 | Multi-valent poly-Ubl chain inhibitors and methods of use | CITY OF HOPE (US) | 2014-08-05 | — | — | US | disclosed |
| US-20140011734-A1 | CYCLIC PEPTIDES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF THE PLATELET ADHESION | SANOFI (FR) | 2014-01-09 | — | — | US | disclosed |
| EP-2598157-A1 | CYCLIC PEPTIDES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF THE PLATELET ADHESION | SANOFI (FR) | 2013-06-05 | — | — | EP | disclosed |
| US-20120302815-A1 | MULTI-VALENT POLY-UBL CHAIN INHIBITORS AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-11-29 | — | — | US | disclosed |
| WO-2012013709-A1 | CYCLIC PEPTIDES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF THE PLATELET ADHESION | SANOFI (FR) | 2012-02-02 | — | — | WO | disclosed |
| US-20070054909-A1 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-08 | — | — | US | disclosed |
| US-7179819-B2 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-02-20 | — | — | US | disclosed |
| US-20040229858-A1 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-11-18 | — | — | US | disclosed |
| US-6756378-B2 | BENZYL -UREA, -THIOUREA, OR -GUANIDINE DERIVATIVES THAT INHIBIT THE BINDING OF LIGANDS TO ALPHA 4 BETA 1 INTEGRIN (VLA-4) | PHARMACOPEIA DRUG DISCOVERY, INC. | 2004-06-29 | — | — | US | disclosed |
| US-20030078249-A1 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220106361-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | PAICS, CYCS, LSS | KMT2A 2834/4885TLR2 4868/4885FABP5 4000/4885 |
| US-20140011734-A1 | CYCLIC PEPTIDES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF THE PLATELET ADHESION | F12, F11, F13B | KMT2A 4818/4885TLR2 3514/4885FABP5 2630/4885 |
| US-12187816-B2 | Macrocyclic compounds and methods of use thereof | PAICS, CYCS, LSS | KMT2A 2834/4885TLR2 4868/4885FABP5 4000/4885 |
| US-20030078249-A1 | VLA-4 inhibitor compounds | VCAM1, ICAM1, ITGA4 | KMT2A 1046/4885TLR2 1257/4885FABP5 471/4885 |
| US-20070054909-A1 | VLA-4 inhibitor compounds | VCAM1, ITGB4, ICAM1 | KMT2A 735/4885TLR2 1209/4885FABP5 436/4885 |
| US-20250129125-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | PAICS, CYCS, LSS | KMT2A 2834/4885TLR2 4868/4885FABP5 4000/4885 |
| US-20120302815-A1 | MULTI-VALENT POLY-UBL CHAIN INHIBITORS AND METHODS OF USE | UFM1, UBAP2L, SUMO1 | KMT2A 935/4885TLR2 3881/4885FABP5 2082/4885 |
| US-20220363719-A1 | Reverse Amide-Linked Melanocortin Receptor-Specific Cyclic Peptides | MC1R, NPY1R, MC3R | KMT2A 2310/4885TLR2 2212/4885FABP5 4169/4885 |
| US-20040229858-A1 | VLA-4 inhibitor compounds | VCAM1, ICAM1, ITGB4 | KMT2A 918/4885TLR2 1164/4885FABP5 417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.